[Efficacy and safety of allapinine and quinidine bisulphate in the treatment of patients with persistent atrial fibrillation after cardioversion].
Kardiologiia
; 54(9): 33-8, 2014.
Article
en Ru
| MEDLINE
| ID: mdl-25702400
ABSTRACT
OBJECTIVE:
To assess and compare the safety and efficacy of allapinine and quinidine bisulphate in the treatment of patients with persistent atrial fibrillation after cardioversion. Design--Prospective, randomised, open study. Patients--73 consecutive patients (men only, mean age 44 ± 11 years) with persisnent atrial fibrillation and flutter. Interventions--37 patients were randomised to allapinine (ALP) (1.5 mg/kg/d), 36 to quinidine bisulphate (QUIN) (15 mg/kg/d) with subsequent successful pharmacological or electrical cardioversion. Main outcome measures--Recurrence of atrial fibrillation or side effects.RESULTS:
In the ALP group 15 of the 37 patients developed atrial fibrillation up to 12 month of follow-up, while in the QUIN group 20 patients developed atrial fibrillation and 5 experienced significant side effects. Relative risk (RR) (ALP vs QUIN) 0.58 (95% CI 0.37-0.91, p < 0.02). The number needed to treat (NNT) was (-3.48) (14.2-1.97 harm). When 5 patients with significant side effects were excluded from the analysis RR was 0.62 (95% CI 0.39-1.0, p = 0.052) and NNT--(-4.1) (122.7-2.1 harm) but power of the study was too low--67%.CONCLUSION:
Allapinine is as effective as quinidine bisulphate in the long term treatment of patients with persistent atrial fibrillation after successful cardioversion but causes significantly less side effects.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Quinidina
/
Fibrilación Atrial
/
Aconitina
/
Cardioversión Eléctrica
Tipo de estudio:
Clinical_trials
/
Etiology_studies
Límite:
Adult
/
Humans
/
Male
/
Middle aged
Idioma:
Ru
Revista:
Kardiologiia
Año:
2014
Tipo del documento:
Article